FDA investigating safety risks in CAR T-cell recipients

被引：14
|
作者：
Nelson, Roxanne
机构：
来源：
LANCET | 2023年 / 402卷 / 10418期
关键词：
D O I：
10.1016/S0140-6736(23)02747-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：2181 / 2181
页数：1
相关论文
共 50 条
  • [1] FDA Investigating CAR-Related T-cell Malignancies
    Rose, Suzanne
    CANCER DISCOVERY, 2024, 14 (01) : 9 - 10
  • [2] Safety of CAR T-cell therapy in kidney transplant recipients
    Mamlouk, Omar
    Nair, Ranjit
    Iyer, Swaminathan P.
    Edwards, Angelina
    Neelapu, Sattva S.
    Steiner, Raphael E.
    Adkins, Sherry A.
    Hawkins, Misha
    Saini, Neeraj
    Devashish, Kartik
    Strati, Paolo
    Mandayam, Sreedhar
    Ahmed, Sairah
    BLOOD, 2021, 137 (18) : 2558 - 2562
  • [3] T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities
    Hu, Jingqiong
    Dunbar, Cynthia E.
    BLOOD, 2024, 144 (24) : 2473 - 2481
  • [4] FDA Approves second CAR T-cell Therapy
    Calmes-Miller, Jordan
    CANCER DISCOVERY, 2018, 8 (01) : 5 - 6
  • [5] FDA requires warnings for T-cell cancer after CAR T-cell therapy
    Reactions Weekly, 2024, 2005 (1) : 3 - 3
  • [6] The Fate(s) of CAR T-Cell Therapy: Navigating the Risks of CAR+ T-Cell Malignancy
    Abou-el-Enein, Mohamed
    BLOOD CANCER DISCOVERY, 2024, 5 (04): : 249 - 257
  • [7] Balancing the risks and benefits of CAR T-cell therapy
    不详
    LANCET HAEMATOLOGY, 2024, 11 (03): : e169 - e169
  • [8] FDA Adds Boxed Warning to CAR T-Cell Therapies, but Says Benefits Outweigh Risks of Secondary Cancers
    Suran, Melissa
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (10): : 889 - 889
  • [9] Epidemiology and Predictors of Readmission in CAR T-Cell Therapy Recipients
    Sharma, Aditi
    Singh, Vijendra
    Deol, Abhinav
    BLOOD, 2021, 138
  • [10] CAR T-Cell Therapy in the Older Person: Indications and Risks
    Geoffrey Shouse
    Alexey V. Danilov
    Andy Artz
    Current Oncology Reports, 2022, 24 : 1189 - 1199
12345